This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
Subscribe To Our Newsletter & Stay Updated
